tovorafenib
4 abstracts
Abstract
Phase IB study of tovorafenib for children with relapsed/recurrent low-grade gliomas and other MAPK pathway activated tumors.Org: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Children's Hospital of Philidelphia, St. Louis Children's Hospital, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Massachusetts General Hospital,
Abstract
Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial.Org: Kids Cancer Centre, Sydney Children's Hospital, University Hospital – Rigshospitalet, Children’s Health Queensland Hospital and Health Service, Department of Paediatric Haematology/Oncology,
Abstract
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.Org: Children's National Hospital, Washington, DC, Duke University, Durham, NC, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX,
Abstract
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ), Children's National Hospital, Washington, DC, Seattle Children’s Hospital, Orlando Health Arnold Palmer Hospital for Children,